References

Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers: III: molecular pathology of kidney cancer

10.1097/pas.0000000000001476 · 2020 · External reference

Renal cell carcinoma

10.1038/nrdp.2017.9 · 2017 · External reference

Downstream targets of VHL/HIF-alpha signaling in renal clear cell carcinoma progression: mechanisms and therapeutic relevance

10.3390/cancers15041316 · 2023 · External reference

Protein lysine acetylation by p300/CBP

10.1021/cr500452k · 2015 · External reference

Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents

10.7150/thno.73223 · 2022 · External reference

The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors

10.1016/j.ctrv.2015.05.004 · 2015 · External reference

LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma

10.1038/bjc.2017.77 · 2017 · External reference

HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma

10.1158/1078-0432.ccr-19-1459 · 2020 · External reference

The acetylase/deacetylase couple CREB-binding protein/sirtuin 1 controls hypoxia-inducible factor 2 signaling

10.1074/jbc.m111.244780 · 2012 · External reference

Coordinate regulation of stress signaling and epigenetic events by Acss2 and HIF-2 in cancer cells

10.1371/journal.pone.0190241 · 2017 · External reference

HIF-2alpha expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma

10.1172/jci164249 · 2024 · External reference

Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2

10.1073/pnas.0811023106 · 2009 · External reference

Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734

10.1182/bloodadvances.2020001879 · 2020 · External reference